{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:05:10Z","timestamp":1789790710421,"version":"4.0.1"},"reference-count":33,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7776-26","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:11:42Z","timestamp":1789423902000},"source":"Crossref","is-referenced-by-count":0,"title":["Characteristics of Patients with Guillain-Barr\u00e9 Syndrome and Fisher Syndrome in Complement Activation: A Retrospective Study"],"prefix":"10.2169","author":[{"given":"Keishu","family":"Murakami","sequence":"first","affiliation":[{"name":"Department of Neurology, Wakayama Medical University, Japan"},{"name":"Department of Molecular Genetics, Wakayama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Department of Neurology, Wakayama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tsujimoto","sequence":"additional","affiliation":[{"name":"Department of Molecular Genetics, Wakayama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoi","family":"Kuwahara","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kindai University Faculty of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimitsu","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Molecular Genetics, Wakayama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuichi","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Department of Neurology, Wakayama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Elendu C, Osamuyi EI, Afolayan IA, et al. Clinical presentation and symptomatology of Guillain-Barr\u00e9 syndrome: a literature review. Medicine (Baltimore) 103: e38890, 2024.","DOI":"10.1097\/MD.0000000000038890"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Godschalk PCR, Kuijf ML, Li J, et al. Structural characterization of Campylobacter jejuni lipooligosaccharide outer cores associated with Guillain-Barr\u00e9 and Miller Fisher syndromes. Infect Immun 75: 1245-1254, 2007.","DOI":"10.1128\/IAI.00872-06"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Koga M, Gilbert M, Li J, et al. Antecedent infections in Fisher syndrome: a common pathogenesis of molecular mimicry. Neurology 64: 1605-1611, 2005.","DOI":"10.1212\/01.WNL.0000160399.08456.7C"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11: 785-797, 2010.","DOI":"10.1038\/ni.1923"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Hafer-Macko CE, Sheikh KA, Li CY, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 39: 625-635, 1996.","DOI":"10.1002\/ana.410390512"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Hafer-Macko C, Hsieh ST, Li CY, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol 40: 635-644, 1996.","DOI":"10.1002\/ana.410400414"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Koski CL, Sanders ME, Swoveland PT, et al. Activation of terminal components of complement in patients with Guillain-Barr\u00e9 syndrome and other demyelinating neuropathies. J Clin Invest 80: 1492-1497, 1987.","DOI":"10.1172\/JCI113231"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kuwabara S, Kusunoki S, Kuwahara M, et al. Efficacy and safety of eculizumab in Guillain-Barr\u00e9 syndrome: a phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial. J Peripher Nerv Syst 29: 339-349, 2024.","DOI":"10.1111\/jns.12646"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sejvar JJ, Kohl KS, Gidudu J, et al. Guillain-Barr\u00e9 syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 29: 599-612, 2011.","DOI":"10.1016\/j.vaccine.2010.06.003"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Minamino M, Miyamoto K, Kuwahara M, et al. Characteristics of Guillain-Barr\u00e9 syndrome in super-elderly individuals. J Neurol 270: 2191-2196, 2023.","DOI":"10.1007\/s00415-023-11567-8"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Yamagishi Y, Suzuki H, Sonoo M, et al. Markers for Guillain-Barr\u00e9 syndrome with poor prognosis: a multi-center study. J Peripher Nerv Syst 22: 433-439, 2017.","DOI":"10.1111\/jns.12234"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ho TW, Mishu B, Li CY, et al. Guillain-Barr\u00e9 syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 118: 597-605, 1995.","DOI":"10.1093\/brain\/118.3.597"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kusunoki S, Chiba A, Kon K, et al. N-acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain-Barr\u00e9 syndrome. Ann Neurol 35: 570-576, 1994.","DOI":"10.1002\/ana.410350510"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Terayama A, Kuwahara M, Yoshikawa K, et al. Takotsubo cardiomyopathy in Guillain-Barr\u00e9 syndrome. J Neurol 271: 4067-4074, 2024.","DOI":"10.1007\/s00415-024-12295-3"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Miyamoto K, Minamino M, Kuwahara M, et al. Complement biomarkers reflect the pathological status of neuromyelitis optica spectrum disorders. Front Immunol 14: 1090548, 2023.","DOI":"10.3389\/fimmu.2023.1090548"},{"key":"16","unstructured":"16. Ohtani K, Inoue N, Hidaka Y, Wakamiya N. The analysis of complement factors and activation markers in normal Japanese individuals. J Jpn Assoc Comple Res 56: 13-22, 2019."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ogawa-Goto K, Funamoto N, Ohta Y, Abe T, Nagashima K. Myelin gangliosides of human peripheral nervous system: an enrichment of GM1 in the motor nerve myelin isolated from cauda equina. J Neurochem 59: 1844-1849, 1992.","DOI":"10.1111\/j.1471-4159.1992.tb11018.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Yuki N, Kuwabara S, Koga M, Hirata K. Acute motor axonal neuropathy and acute motor-sensory axonal neuropathy share a common immunological profile. J Neurol Sci 16: 121-126, 1999.","DOI":"10.1016\/S0022-510X(99)00180-X"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Koga M, Yuki N, Hirata K, Morimatsu M, Mori M, Kuwabara S. Anti-GM1 antibody IgG subclass: a clinical recovery predictor in Guillain-Barr\u00e9 syndrome. Neurology 60: 1514-1518, 2003.","DOI":"10.1212\/01.WNL.0000061615.77865.83"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Yanaka S, Yogo R, Watanabe H, et al. On-membrane dynamic interplay between anti-GM1 IgG antibodies and complement component C1q. Int J Mol Sci 21: 147, 2019.","DOI":"10.3390\/ijms21010147"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Karbian N, Eshed-Eisenbach Y, Zeibak M, et al. Complement-membrane regulatory proteins are absent from the nodes of Ranvier in the peripheral nervous system. J Neuroinflammation 20: 245, 2023.","DOI":"10.1186\/s12974-023-02920-9"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Gong Y, Tagawa Y, Lunn MPT, et al. Localization of major gangliosides in the PNS: implications for immune neuropathies. Brain 125: 2491-2506, 2002.","DOI":"10.1093\/brain\/awf258"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Ito M, Matsuno K, Sakumoto Y, Hirata K, Nobuhiro Y. Ataxic Guillain-Barr\u00e9 syndrome and acute sensory ataxic neuropathy form a continuous spectrum. J Neurol Neurosurg Psychiatry 82: 294-299, 2011.","DOI":"10.1136\/jnnp.2010.222836"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Sekiguchi Y, Misawa S, Shibuya K, et al. Patterns of sensory nerve conduction abnormalities in Fisher syndrome: more predominant involvement of group Ia afferents than skin afferents. Clin Neurophysiol 124: 1465-1469, 2013.","DOI":"10.1016\/j.clinph.2013.01.020"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Hughes RAC, Cornblath DR, Jacobs BC, van Doorn PA. Guillain\u2010Barr\u00e9 Syndrome Disability Scale. J Peripher Nerv Syst 30: e70064, 2025.","DOI":"10.1111\/jns.70064"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Willison HJ, Veitch J. Immunoglobulin subclass distribution and binding characteristics of anti-GQ1b antibodies in Miller Fisher syndrome. J Neuroimmunol 50: 159-165, 1994.","DOI":"10.1016\/0165-5728(94)90042-6"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Yu J, Yuan X, Chen H, Chaturvedi S, Braunstein EM, Brodsky RA. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood 136: 2080-2089, 2020.","DOI":"10.1182\/blood.2020008248"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Liu JX, Willison HJ, Pedrosa-Domell\u00f6f F. Immunolocalization of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles. Investigative Ophthalmology and Visual Science 50: 3226-3232, 2009.","DOI":"10.1167\/iovs.08-3333"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Iwasa K, Furukawa Y, Yoshikawa H, Yamada M, Ono K. CD59 expression in skeletal muscles and its role in myasthenia gravis. Neurol Neuroimmunol Neuroinflamm 10: e200057, 2022.","DOI":"10.1212\/NXI.0000000000200057"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Kusner LL, Satija N, Cheng G, Kaminski HJ. Targeting therapy to the neuromuscular junction: proof of concept. Muscle and Nerve 49: 749-756, 2014.","DOI":"10.1002\/mus.24057"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Jacobs BC, Koga M, van Rijs W, et al. Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barr\u00e9 syndrome. J Neuroimmunol 194: 181-190, 2008.","DOI":"10.1016\/j.jneuroim.2007.11.017"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Uetz-von Allmen E, Sturzenegger M, Rieben R, Rihs F, Frauenfelder A, Nydegger UE. Antiganglioside GM1 antibodies and their complement activating capacity in central and peripheral nervous system disorders and in controls. Eur Neurol 39: 103-110, 1998.","DOI":"10.1159\/000007916"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Uncini A, Vallat JM, Jacobs BC. Guillain-Barr\u00e9 syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic. J Neurol Neurosurg Psychiatry 10: 1105-1110, 2020.","DOI":"10.1136\/jnnp-2020-324491"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7776-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:30:50Z","timestamp":1789788650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7776-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":33,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7776-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7776-26"}}